US2018338958A1PendingUtilityA1

Method of treatment using inhibitors of mitosis

56
Assignee: ARRAY BIOPHARMA INCPriority: Oct 16, 2008Filed: Jun 5, 2018Published: Nov 29, 2018
Est. expiryOct 16, 2028(~2.2 yrs left)· nominal 20-yr term from priority
Inventors:Brian J. TunquistDuncan WalkerRichard D. Woessner
A61K 31/00A61P 35/00A61K 31/433
56
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Methods of treating diseases caused by cell division or that are treated by inhibiting mitosis by administering two doses of an inhibitor of mitosis between the biologically effective dose and the maximum tolerated dose in a dosing cycle that allows for the recovery or subsiding of side effects, wherein the second dose is administered 24 to 48 hours after the first dose.

Claims

exact text as granted — not AI-modified
1 - 47 . (canceled) 
     
     
         48 . A method of treating cancer by administering to a patient in need thereof two doses of (S)-2-(3-aminopropyl)-5-(2,5-difluorophenyl)-N-methoxy-N-methyl-2-phenyl-1,3,4-thiadiazole-3(2H)-carboxamide an inhibitor of mitosis selected from the group consisting of the '161 KSP Inhibitors between the biologically effective dose and the maximum tolerated dose in a 14 to 21 day dosing cycle, wherein the first dose is administered on day one of the dosing cycle and the second dose is administered on day two or day three of the dosing cycle. 
     
     
         49 . A method of  claim 48 , wherein the dosing cycle is 14 days. 
     
     
         50 . A method of  claim 48 , wherein the dosing cycle is 21 days. 
     
     
         51 . A method of  claim 49 , wherein the second dose is administered on day two of the dosing cycle. 
     
     
         52 . A method of  claim 50 , wherein the second dose is administered on day two of the dosing cycle. 
     
     
         53 . A method of  claim 49 , wherein the second dose is administered on day three of the dosing cycle. 
     
     
         54 . A method of  claim 50 , wherein the second dose is administered on day three of the dosing cycle. 
     
     
         55 . A method of  claim 51 , wherein the two doses are at the maximum tolerated dose. 
     
     
         56 . A method of  claim 52 , wherein the two doses are at the maximum tolerated dose. 
     
     
         57 . A method of  claim 53 , wherein the two doses are at the maximum tolerated dose. 
     
     
         58 . A method of  claim 54 , wherein the two doses are at the maximum tolerated dose. 
     
     
         59 - 70 . (canceled) 
     
     
         71 . A method of  claim 55 , wherein the cancer is a hematological tumor. 
     
     
         72 . A method of  claim 56 , wherein the cancer is a hematological tumor. 
     
     
         73 . A method of  claim 57 , wherein the cancer is a hematological tumor. 
     
     
         74 . A method of  claim 58 , wherein the cancer is a hematological tumor. 
     
     
         75 - 78 . (canceled) 
     
     
         79 . A method of  claim 71 , wherein the cancer is selected from advanced myeloid leukemia, relapsed multiple myeloma and refractory multiple myeloma. 
     
     
         80 . A method of  claim 72 , wherein the cancer is selected from advanced myeloid leukemia, relapsed multiple myeloma and refractory multiple myeloma. 
     
     
         81 . A method of  claim 73 , wherein the cancer is selected from advanced myeloid leukemia, relapsed multiple myeloma and refractory multiple myeloma. 
     
     
         82 . A method of  claim 74 , wherein the cancer is selected from advanced myeloid leukemia, relapsed multiple myeloma and refractory multiple myeloma. 
     
     
         83 - 137 . (canceled)

Join the waitlist — get patent alerts

Track US2018338958A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.